Clinical patterns of mucormycosis in northwest India
May 16 2018
Shockingly, the prevalence of mucormycosis in India (0.14 cases/1000 population) has previously been estimated to be around 70 times that of the worldwide rate.
A new survey was recently published by Dr Jagdish Chander and colleagues at the Government Medical College Hospital (Chandigarh, northwest India). In total 82 patients over 5 years were diagnosed with mucormycosis, of whom 67% were male, 62% were diabetic, and 15% had recently received an intramuscular injection. Presentation was frequently rhino-orbital-cerebral (45%), cutaneous (30%) or pulmonary (17%). The most frequently-isolated agent was Rhizopus.
Despite antifungal therapy (mainly amphotericin B) being commenced for most patients, mortality rates were high: 25 patients (30%) died and a further 8 (10%) were at high risk because they left the hospital against medical advice.
What can I do?
Nip it in the bud. Tissue invasion and mortality are rapid, so if mucormycosis is suspected then commence antifungal therapy and perform surgical debridement without delay.
Proportions of species isolated in mucormycosis cases in Chander et al (2018)